How does AOD-9604 specifically target and reduce stubborn fat cells without affecting lean muscle mass?

AOD-9604, a modified fragment of human growth hormone, selectively stimulates lipolysis in adipose tissue while inhibiting lipogenesis, as demonstrated in numerous preclinical and clinical studies. Its mechanism involves interaction with beta-3 adrenergic receptors, leading to the release of fat from stubborn adipocytes, without the systemic growth-promoting effects or insulin resistance associated with full HGH.

Is Tesamorelin effective against visceral fat, particularly in individuals without HIV-associated lipodystrophy?

Yes, Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, has shown significant efficacy in reducing visceral adipose tissue (VAT) in clinical trials, including those involving non-HIV populations. Research indicates it can reduce VAT by approximately 15-20% through stimulating endogenous growth hormone release, offering a targeted approach to deeply embedded stubborn fat.

What are the typical research-level dosages and administration methods for MOTS-c when investigating its effects on localized stubborn fat?

In research settings, MOTS-c is commonly administered subcutaneously, with typical experimental dosages ranging from 5-10 mg per week, often divided into multiple injections. Studies suggest this localized delivery can enhance its metabolic signaling, particularly in areas rich in mitochondria, which may contribute to its observed effects on fat metabolism in stubborn adipose tissue.

Among the peptides extensively researched for stubborn fat, which ones show the most promising evidence for targeting lower abdominal or flank fat?

AOD-9604, Tesamorelin, and MOTS-c stand out for their documented effects on stubborn fat zones. AOD-9604 directly promotes fat oxidation, Tesamorelin significantly reduces visceral fat, and MOTS-c enhances mitochondrial function, all contributing to the reduction of adipose tissue in challenging areas like the lower abdomen and flanks, as supported by multiple clinical and preclinical investigations.

How do peptide researchers define 'stubborn fat zones' and what biological characteristics make these areas resistant to conventional fat loss?

In peptide research, 'stubborn fat zones' refer to adipose tissue, typically found in the lower abdomen, hips, and thighs, characterized by a higher density of alpha-2 adrenergic receptors and lower blood flow, making fat release more difficult. Peptides like AOD-9604 are studied for their ability to bypass or counteract these biological hurdles, promoting lipolysis where it's typically resistant.

PeptideKey Health Goals

Stubborn Fat Zones: Peptides Ranked for Lipolysis [2026]

AOD-9604, tesamorelin, and MOTS-c for targeted fat loss. Which peptides address stubborn adipose tissue and what the research actually supports.

This goal guide is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.